PE-22-28 // Rapid Antidepressant
A sortilin-derived peptide that blocks TREK-1 potassium channels for rapid antidepressant-like effects. Enhances serotonergic neurotransmission through a completely novel mechanism — faster onset than SSRIs, without the weeks-long delay. A new class of antidepressant peptide targeting ion channels instead of reuptake.
A completely new antidepressant pathway.
SSRIs block serotonin reuptake — a mechanism discovered in the 1970s that takes 2–6 weeks to produce clinical effects. PE-22-28 blocks TREK-1 potassium channels, which directly enhances serotonergic neuron firing with rapid onset. A fundamentally different approach.
Daily subcutaneous injection.
PE-22-28 uses a straightforward daily SubQ injection protocol. The rapid-onset mechanism means effects may be noticeable within days rather than the weeks required for SSRIs.
From spadin to PE-22-28.
PE-22-28 is derived from research on spadin, a natural peptide released from the sortilin receptor that was found to block TREK-1 channels. Catherine Bhatt and Marc Bhatt's work at the CNRS in France established TREK-1 as a novel antidepressant target.
TREK-1 knockout mice show a depression-resistant phenotype — they don't develop learned helplessness or anhedonia in standard depression models. Pharmacological blockade of TREK-1 by spadin and its analogs reproduces this antidepressant effect.
PE-22-28 is an optimized analog of spadin with improved stability and potency. Preclinical studies showed rapid antidepressant-like effects in behavioral models within days of administration — significantly faster than the 2-6 week onset of SSRIs. Human data remains extremely limited.
Antidepressant mechanism comparison.
| Compound | Mechanism | Onset | Route | Status |
|---|---|---|---|---|
| PE-22-28 | TREK-1 Block + Sigma-1 | Days | SubQ | Research |
| SSRIs | Serotonin Reuptake | 2–6 weeks | Oral | FDA Approved |
| Ketamine | NMDA Antagonist | Hours | IV/Nasal | FDA (esketamine) |
| Selank | GABA + 5-HT Modulation | Days | Intranasal | Approved (Russia) |
What to watch for.
PE-22-28's side effect profile is manageable with proper protocol adherence. Baseline blood work before starting and periodic monitoring during use is essential.
- Very limited human safety data
- Injection site reactions (expected)
- Theoretical serotonergic effects (monitor)
- Do NOT combine with SSRIs/SNRIs without medical guidance
- Do NOT combine with MAOIs
- Novel mechanism — long-term effects unknown
- Serotonin levels (if available)
- Comprehensive metabolic panel
- Liver enzymes (ALT, AST)
- Complete blood count
- Mood assessment scales (PHQ-9, GAD-7)
- Cortisol (stress axis)
- Do NOT combine with SSRIs/SNRIs without medical supervision (serotonin risk)
- Do NOT combine with MAOIs
- Selank for anxiolytic support (different mechanism — safer combination)
- Semax for cognitive enhancement alongside mood improvement
- BPC-157 for neuroprotective support
- Requires medical guidance — this is a mood-altering compound
- Lyophilized: refrigerate at 2–8°C
- Reconstituted: refrigerate, use within 14 days
- Protect from light
- Do not freeze reconstituted solution
- Research compound — limited storage data
Compounds that complement PE-22-28.
A genuinely novel antidepressant mechanism — but proceed carefully.
PE-22-28 represents something rare in psychiatry: a truly new mechanism of action. TREK-1 channel blockade is not a variation on serotonin reuptake — it's a fundamentally different pathway to the same endpoint. The rapid-onset preclinical data is promising, but human data is extremely limited. This is not a DIY compound. If you're on prescribed antidepressants, do not modify your medications based on peptide research. If you're working with a physician who understands peptide protocols, PE-22-28 may represent a research avenue worth discussing. Stack cautiously — serotonergic interactions are the primary safety concern.
Our free Protocol Guide includes cognitive and mood peptide protocols — PE-22-28 context, Selank/Semax stacking, and monitoring templates.